Requests that the FDA to determine whether the Reference Listed Drug (RLD) DEXAMETHASONE ELIXIR, 0.5 mg/5 mL; Abbreviated New Drug Application (ANDA) 088254 of PHARMOBEDIENT CONSULTING has been voluntarily withdrawn from sale for safety or efficacy reasons. | Federal Regulations · Congress.wiki

Nonrulemaking

FDA

FDA-2026-P-1306

Requests that the FDA to determine whether the Reference Listed Drug (RLD) DEXAMETHASONE ELIXIR, 0.5 mg/5 mL; Abbreviated New Drug Application (ANDA) 088254 of PHARMOBEDIENT CONSULTING has been voluntarily withdrawn from sale for safety or efficacy reasons.

Documents

Comments

Description

CLOSED

Key Dates

Comment Period OpensFeb 5, 2026

Documents

Type	Title	Posted	Comments	Status
Other	Response Letter	May 6, 2026	--

Keywords

CDER

Citizen Petition

Lachman Consultant Services Inc

determine whether the Reference Listed Drug

DEXAMETHASONE ELIXIR 0 5 mg 5 mL

Abbreviated New Drug Application 088254

of PHARMOBEDIENT CONSULTING

has been voluntarily withdrawn

Data from Regulations.gov